InspireMD Inc New (NSPR)

InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket tradingMarch 18, 2026 11:09 AM
IH Market News
InspireMD Inc. (NASDAQ:NSPR) reported stronger-than-expected fourth-quarter results for 2025, beating both earnings and revenue forecasts as sales accelerated following the U.S. launch of its CGuard Prime device.The company posted earnings per share of -$0.14 for the quarter, outperforming analyst expectations of -$0.19. Revenue reached $3.15 million, well above the forecast of $2.32 million. Following the announcement, InspireMD shares climbed about 12.8% in premarket trading to roughly $2.02.



Revenue growth driven by U.S. market



Total revenue rose 62% year over year to about $3.1 million, up from $1.9 million in the same quarter of 2024. The increase was largely fueled by the commercial rollout of the CGuard Prime carotid stent in the United States after receiving FDA approval in June 2025.The company said the shift toward higher U.S. sales improved its revenue mix and helped boost margins. U.S. revenue reached approximately $866,000 during the quarter, representing a 74% sequential increase.Gross profit totaled about $1.2 million, equivalent to 37.5% of revenue.For the previous twelve months through the third quarter of 2025, InspireMD reported total revenue of $7.78 million with a gross margin of roughly 25%. The company also reported a strong liquidity position, with a current ratio of 6.51, indicating that liquid assets significantly exceed short-term liabilities.



Market reaction



Investors reacted positively to the results, sending the stock higher in premarket trading after the announcement. The move reflected confidence in the company’s ability to grow revenue and expand in the U.S. market following regulatory approval of its flagship device.



Outlook and product development



Looking ahead, InspireMD expects continued revenue growth supported by the expansion of the CGuard Prime platform in the United States.The company is also working on a next-generation delivery system designed to improve technical performance and ease of use. That product is expected to be introduced in the fourth quarter of 2026.Analysts have recently revised their earnings estimates upward, and current price targets range between $4 and $6 per share.“Our Q4 results reflect the successful execution of our strategy to penetrate the U.S. market with CGuard Prime, and we are excited about the future growth opportunities as we continue to expand our product offerings and market presence,” said CEO Marvin Slosman.



Risks and challenges



Despite the strong quarterly performance, several risks remain. Delays in regulatory approvals for future products could slow growth, while increasing competition in the carotid intervention market may pressure margins. Supply chain disruptions could also affect manufacturing and delivery timelines, and broader economic conditions may influence healthcare spending.



Focus on expansion strategy



During the earnings call, analysts asked about the timeline for FDA approval of the TCAR-indicated CGuard Prime stent, which the company expects in the third quarter of 2026. Executives also addressed plans for managing operating expenses while expanding in the U.S. market, emphasizing a measured growth strategy aimed at balancing expansion with financial discipline.InspireMD stock price

Original: InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading

Absolute garbage. Anyone pumping it is a garbage person too. We know they're doing a at the market share dumping... They ain't getting any sales anytime soon either on their Newly FDA approved product... 
I'm only offering fair warning based on how it traded After Hours and looking back over the past few years, garbage, absolute garbage 
And in quarter 1 they reported about 1 million dollars, LOL GTFO of here with that petty income...I as a small business operator can gross half a million dollars in a quarter... This is a publicly traded company using Shareholders money and lenders... It is literally a Bottomless Hole of Cash Injection from other people lol...
Stupid of me to buy this,  thankfully ima sell at a loss for $300

STAY AWAY FROM THIS TICKER, IT'S A DUMP... FDA APPROVAL OR NOT, Look at the past few trading years... Even if it goes up to $3 to $4 in the coming days... IT'S ABSOLUTE GARBAGE, either they're dumping their own shares or shareholders are dumping in After Hours, but I've been watching it since the dump from $4... Each time it grows a few cents, someone dumps it right back a few cents. 
Keep your money safe and away from garbage like this

Who the Fuk keeps dumping on the way up to 2.40s
I would Stay the HELL away from this ticker, I've been watching it for an hour and half... every time it gets to 2.38 - 2.40 ---- DUMPED LOL
It's at 2.35 right now, watch it happen again... LOL

The Company’s announcement of FDA approval of the CGuard Prime Carotid Stent System triggers the second of four milestone-driven warrant tranches pursuant to the private placement financing of up to $113.6 million announced in May 2023. Gross proceeds from this warrant tranche are expected to be $17.9M if exercised in full. Proceeds, if any, will be used to support the imminent commercial launch of the CGuard Prime Carotid Stent System in the United States, initiating new regulatory pathways for advanced applications of our CGuard stent platform, and developing new products, while at the same time continuing to develop our business outside of the United States. Warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board members.
https://finviz.com/news/87528/inspiremd-announces-fda-approval-for-cguard-prime-carotid-stent-system-for-the-prevention-of-stroke

buy signal confirmed yesterday.. but volume still anemic...

Clock for the fda decision started in Oct.. waiting the decision date
to be announced.

Chart is showing the 'sentiment' for the shares is starting to 'change'...

Got to figure out how to post an 'image' of a screenshot I took off my charts vs
something with a web address.

Own shares, now in it for the run to the approval decision.
One of my remaining questions was, what kind of 'revenue' stream
do they see possible.
And if you get a chance, go to their website and listen to the webcast
of the QTRLY call they just had.
Kind of confirms this could see the share price at least double, which is my
'goal', and likely some more. $10/sh could even be in play although
one has to acknowledge, the 'markey' they are selling into has 'limitations' in terms
of how many 'end users' there is that could benefit from their design. Then there is
the question of, how much of the market will their design capture from the existing
that remains to be answered.

Disclaimer: own shares, in it now for the fda decision

Cut my 'losses' on the prior purchases when the chart brokedown.

Just took new positions today at $2.56.

Will likely add IF/when it starts to advance...

Target price: $4.5

IF that happens, be about a 75% return.

-See they now have a US based office to operate out of.
-NDA is under review
-fda decision expected in the 1st half of 2025.
-Looking at their website, have had a weak recognition
of the possible revenue stream for them in terms of sales. But
they have a presentation that seems to imply it might be pretty big
in terms of potential sales.

Disclaimer: do own shares that I now plan to ride for the decision

Time to start preparing to nibble on some shares..
Data is 'in' from the PH 3. Has the expectation of a 1st half 2025 decision.
SHOULD get approval, but ya just never know if the fda will 'protect' the
big pharmas cash flow or not anymore by slowing down the 'competition'

Chart is saying the share price is under 'pressure' even as it trys to hold the $2.50
share price.. Agree with the current target price of $4.5 mainly cause its 'conservative',
and not sure how well the US market will adapt to this Israeli based development.

Disclaimer: have made a couple of small buys now sub $2.8 and $2.7. Decided those
buy in prices were ok to get a toehold and still get a decent return IF it can see $4+..
Will be patient to add more now, patient to let the chart confirm sentiment for the shares
is trending 'up' first.

They all go up

NSPR should crash to $0.258048 to be fair considering its recent Over Triple Super-Heavy Huge OS Dilutions --- from 8M shares (when it hit $0.8064) to over 25M shares now! The recent low was $0.8064 anyway!

Sell this Pos Scam at the bids ASAP before it is too late! Then use all the cash proceeds to buy its Mostly Valuable NASDAQ EV peers (such as KXIN: Super-Ridiculous-Low $4,044,292 Market Value with Huge BV/PPS Ratio 12.121 v.s. NSPR has Super-Ridiculous-High $98,970,584 Market Value with Super Tiny BV/PPS Ratio 0.625) to recover all the Huge Losses here! Note, KXIN ever soared to $0.6 in Premarket session just a few months ago!

The Book Value here has already crashed down 75% while the Cash Value here has already crashed down 80% since NSPR hit its recent low $0.8064!

So, sell NSPR ASAP before it creates A Series Of New Lows until it hits $0.258048 in the coming weeks/months...

Any thing is possible with low priced junk

NSPR should crash to $0.258048 to be fair considering its recent over Triple Super-Heavy OS Huge dilutions! The recent low was $0.8064 anyway!

Sell the Pos Scam at the bids ASAP before it is too late... Then use all the cash proceeds to buy its Most Valuable NASDAQ EV peer (KXIN: Super-Ridiculous-Low $5M MV) to recover all the Huge Losses here!

NSPR under $3

The company's Debts had already inflated to $2.064M from $1.261M when NSPR hit $0.8064!

So, sell NSPR ASAP before it hits A New Low $0.4927 in the coming days/weeks...

The Book Value here has already crashed down nearly 50% while the Cash Value here has already crashed down 61% since NSPR hit its recent low $0.8064!

So, sell NSPR ASAP before it creates A Series Of New Lows $0.4032 ~ $0.3145 in the coming weeks/months...

Why NSPR created the New 52-week-high $3.85 while the OS was diluted 200% to 25M shares from 8M shares when it hit $0.8064 in last October?

So, a new 52-week-low $0.258048 will be created before the end of this year (2024)...

When NSPR crashed to $0.8064 it only had 8M shares OS! But now the OS was already diluted over 200% to 24,929,825 or 25M shares as of 05/09/2024 alone! So, the new 52-week-low will crash to $0.258048 to be fair!

Kind of nice to see it pulling back from its highs. At this stage, hopefully folks took the gains it gave with a disclaimer that I did sell out way too soon as I didn't see the run getting as crazy as it did.

But that said, liking the pullback. Chart is suggesting more downside is 'possible'. Given that they won't complete the study until in 2024? IF this market continues to 'sour', expecting it to get 'cheaper'..
Disclaimer: like it, but own none at the moment. Just checking into see if anyone had anything to say..

Why NSPR went up so much while its OS had just been diluted by nearly Three-Baggers? Who currently hold those Newly-Diluted 12,887,999 shares?

Note, the Cash Value is only mere $0.54344 a share but its price was up to $3.77 a share most recently! Why this stock's price could be as much as nearly SEVEN Times of its actual Cash Value?

Anyway its Book Value is only $2.204 a share!

Will NSPR crash back to its 52-week-low $0.8064 again in the coming weeks/months?

Well, now the CH7 Bankruptcy seems impossible in the short term for NSPR based on its improved new balance sheet from the latest financial report.

The OS of NSPR had been diluted to 21,244,393 shares on 09/09/2023 from 8,356,394 shares on 05/14/2023! Why such huge dilutions in such short period?

NSPR had already bounced up significantly --- Up 4.68-Bagger or 367.51% to $3.77 so far from its Bottom $0.8064!

InspireMD Inc NASDAQ: NSPR

GoSymbol lookup
Health Care : Health Care
Equipment & Supplies | Small Cap Value | Based in IsraelCompany profile
InspireMD, Inc. is a medical device company. The Company is focusing on the development and
commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary
disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in
stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet
and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

NSPR new 52 week high

Had bought a few thousand shares @ $1.35 and lower range.. Sold them on this pop at around $1.90. Long ways to the 1st qtr 2024 when this trial ends..

Hopefully the share price retries the $1.50 or below level.. Would like to buy another round..

Anything is possible, but my 1st target price range is $3 - 4, maybe $5.

Reasons:
1. established competition, going to have to demo they are 'worth' being the one 'desired'

2. non-US based company. Will the market embrace them, give them a favorable share price

And of course, is WHEN is it 'possible' and that won't be until the end of the Ph 3 monitoring period is complete in my estimation. Which of course is into early 2024

But in the act of disclosure, just starting to accumulate shares figuring a 2-3x return from this price range would be pretty darn good.

Could NSPR soar back to its recent high $22.2 again? The Analyst's Target is $5 anyway!

Note, only 8M shares of Super Tiny OS count!

Will NSPR spike the Same 55-Bagger like its OTC peer did recently?

Note, NSPR did surge 5.1035-Bagger from previous Bottom $4.35 on 09/24/2020 to its recent high $22.2 on 02/11/2021 when all least expected! Which means it can Easily bounce to $4.12 with the Same performance...

Could NSPR soar back to its recent high $22.2 again? The Analyst's Target is $5 anyway!

Note, only 8M shares of Super Tiny OS count!

Will NSPR spike the Same 55-Bagger like its OTC peer (PBHG: from 0.0001 to 0.0055) did recently?

Challenges

What I THINK I know:
-1st qtr 2023, expected to complete enrollment
-1st qtr 2024 timeframe: end of the 12 month follow up monitoring
-2nd qtr 2024 (maybe??): PH 3 trial results
-9 months or so later: up for an FDA decision, so likely at the earliest, end of 2024 for the approval decision (??) 2+ YEARS from now
-still working to expand sales in overseas markets, but realistically, needs the US market approval

That said, then there is the bigger challenge to come and that is, breaking in/capturing market share from some established big market players who
i doubt will easily see their revenue stream 'interrupted' by an upstart. So the question will end up being one of, is this that much better than whats on the market NOW. Will it be that much better that a shift will occur simply because of the advantages/benefits of the design or will the market say, what we have is 'good enough' and the design is a tough sell, slow to gain market share if any.

As a disclaimer: I finally bought a few thousand shares at $1.14. And I plan to add more simply for the PR events to come (ie, completed enrollment, any planned data releases, NDA filing, et al cause they do get the markets attention. So while I expect there to be opportunities to see gains develop from this price level, I am not sold that this WILL get a good toe hold in the US market at this point in time. But given the low share count, I do see a move to $4-5/sh from this price level as achievable. Which is why I wanted 'some shares' before I get surprised by a jump for something I didn't see coming.

NSPR might take off anytime from now on and surge back to its recent high $22.2 again very soon when we least expect it because this NASDAQ Bio-Tech Hidden Gem only has mere 8.3M shares of Super Tiny OS count...

This Hidden Gem should run the Same 5.2-Bagger Quick rally first to hit $7.228 like its OTC peer (PBHG: from previous Bottom 0.0005 to 0.0026) did most recently!

Note, NSPR will surge to a New 52-week-high $7.094 from current 52-week-low $1.39 based on the Same past bouncing performance --- from previous Bottom $4.35 (on 09/24/2020) to its recent high $22.2 (on 02/11/2021)!

Can NSPR hit $22.2 again in the coming months?

NSPR might take off anytime from now on and surge back to its recent high $22.2 again very soon when we least expect it because this NASDAQ Bio-Tech Hidden Gem only has mere 8.3M shares of Super Tiny OS count...

want to get shares, but having to wait for another one to get over a hurdle.

So not in a hurry to see this one 'take off'.. till at least into the 3rd, preferrably the 4th qtr

NSPR should surge to a New 52-week-high $9.75 based on last year's the Same bouncing performance --- from previous Bottom $4.35 (on 09/24/2020) to its recent high $22.2 (02/11/2021)!

No. I called in the company and the management said that NSPR has ZERO Debt and Very Positive Cash Value & Book Value! Therefore there is no way to file the bankruptcy based on current Strong financial balance sheet!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167338599

maybe thats how

With only 8.3M shares of the Super Tiny OS count how could NSPR crash to such ridiculous low price levels?

NSPR had already crashed to $1.91! Its most recent high was $5.06 anyway!

NSPR crashed to $2.83! There is a rumor: the CH7 Bankruptcy will be filed in the coming days which is why the Endless price crashes and A Series Of New All-Time Lows during the past a month...

Sell this Huge Diluting Pos Scam ASAP before it is too late!

The Huge Diluting Pos Scam crashed to $3.11 last Friday! Sell ASAP because NSPR will test the Bottom $3.11 again in the coming days/weeks...

When can you see its most recent high $5.06 again? In the January of 2022?

How could NSPR surge to eye-popping high $22.2 back to this February? What drove this Huge Quick rally?

Can NSPR surge to $17.09 before the end of 2022 in order to bounce the Same 5.4951-Bagger as before --- from previous Bottom $4.04 to $22.2?

The Huge Diluting Pos Scam crashed to $3.41 today! Sell ASAP because NSPR will test the Bottom $3.19 again in the coming days/weeks...

This Huge Diluting Pos Scam just crashed to Another New 52-week-low $3.19 today! Sell ASAP...

This Huge Diluting Pos Scam just crashed to Another New 52-week-low $3.395 today! Sell ASAP...

How could it surge to eye-popping high $22.2 back to this February? What drove this Huge Quick rally?

Can NSPR hit $18.66 again to bounce the Same percentage as before --- from previous Bottom $4.04 to $22.2?

The Huge Diluting Pos Scam just crashed to a New 52-week-low $3.45 yesterday! Sell ASAP...

Why this Pos Scam could go up to $22.2 recently? $5.06 is a New Top!

So it should test the Bottom $3.6 as soon as this week...

NSPR chart